Agilent Technologies, Inc. (NYSE:A)‘s stock had its “buy” rating reaffirmed by research analysts at Barclays PLC in a report issued on Wednesday, July 19th. They currently have a $67.00 target price on the medical research company’s stock. Barclays PLC’s target price indicates a potential upside of 7.82% from the company’s previous close.
A has been the topic of a number of other reports. Deutsche Bank AG reissued a “buy” rating and set a $66.00 price target on shares of Agilent Technologies in a report on Thursday, June 22nd. BidaskClub lowered Agilent Technologies from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 13th. BTIG Research raised their price objective on Agilent Technologies from $57.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, May 24th. Zacks Investment Research upgraded Agilent Technologies from a “hold” rating to a “buy” rating and set a $63.00 price objective for the company in a research report on Tuesday, May 16th. Finally, Jefferies Group LLC lifted their price target on Agilent Technologies from $59.00 to $66.00 and gave the stock a “buy” rating in a research report on Tuesday, May 23rd. Three research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $57.55.
Agilent Technologies (NYSE A) traded up 4.65% during trading on Wednesday, hitting $62.14. The stock had a trading volume of 6,887,905 shares. Agilent Technologies has a 52 week low of $42.92 and a 52 week high of $62.42. The company has a 50-day moving average of $60.10 and a 200 day moving average of $55.96. The company has a market cap of $19.97 billion, a price-to-earnings ratio of 34.93 and a beta of 1.30.
Agilent Technologies (NYSE:A) last released its quarterly earnings results on Tuesday, August 15th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.52 by $0.07. The firm had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.09 billion. Agilent Technologies had a return on equity of 16.49% and a net margin of 13.41%. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same period last year, the business posted $0.49 EPS. On average, equities research analysts anticipate that Agilent Technologies will post $2.23 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Agilent Technologies, Inc. (A) Earns Buy Rating from Barclays PLC” was reported by BBNS and is the sole property of of BBNS. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://baseballnewssource.com/markets/agilent-technologies-a-buy-rating-reaffirmed-at-barclays-plc-updated-updated-updated/1251776.html.
In other news, insider Patrick Kaltenbach sold 5,000 shares of the business’s stock in a transaction on Thursday, July 13th. The shares were sold at an average price of $61.26, for a total transaction of $306,300.00. Following the sale, the insider now directly owns 45,138 shares of the company’s stock, valued at $2,765,153.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael R. Mcmullen sold 50,000 shares of the business’s stock in a transaction on Tuesday, May 23rd. The shares were sold at an average price of $59.86, for a total transaction of $2,993,000.00. The disclosure for this sale can be found here. Insiders sold 112,608 shares of company stock valued at $6,737,509 in the last three months.
Several large investors have recently made changes to their positions in A. Balentine LLC raised its stake in shares of Agilent Technologies by 2.9% in the second quarter. Balentine LLC now owns 1,794 shares of the medical research company’s stock worth $106,000 after buying an additional 50 shares during the period. Cribstone Capital Management LLC raised its stake in Agilent Technologies by 2.3% in the first quarter. Cribstone Capital Management LLC now owns 2,359 shares of the medical research company’s stock valued at $125,000 after buying an additional 54 shares during the last quarter. Sun Life Financial INC raised its stake in Agilent Technologies by 26,144.4% in the second quarter. Sun Life Financial INC now owns 2,362 shares of the medical research company’s stock valued at $140,000 after buying an additional 2,353 shares during the last quarter. Acrospire Investment Management LLC raised its stake in Agilent Technologies by 92.3% in the second quarter. Acrospire Investment Management LLC now owns 2,500 shares of the medical research company’s stock valued at $148,000 after buying an additional 1,200 shares during the last quarter. Finally, Parallel Advisors LLC raised its stake in Agilent Technologies by 5.3% in the second quarter. Parallel Advisors LLC now owns 2,623 shares of the medical research company’s stock valued at $157,000 after buying an additional 131 shares during the last quarter.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with our FREE daily email newsletter.